Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
The European Journal of Health Economics
Published in: The European Journal of Health Economics 8/2014

01-11-2014 | Original Paper

Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model

Authors: G. Feljandro P. Ramos, Antoinette D. I. van Asselt, Sandra Kuiper, Johan L. Severens, Tanja Maas, Edward Dompeling, J. André Knottnerus, Onno C. P. van Schayck

Published in: The European Journal of Health Economics | Issue 8/2014

Login to get access

Abstract

Background

Many children stand to benefit from being asthma-free for life with primary (i.e., prenatally started) prevention addressing one environmental exposure in a unifaceted (UF) approach or at least two in a multifaceted (MF) approach. We assessed the cost-effectiveness of primary prevention programmes for Dutch children in a decision-analytic framework.

Methods

A decision-analytic tree model analysing healthcare costs and asthma cases prevented was developed to compare usual care (UC) with two UF and three MF programmes on the primary prevention of asthma amongst children. Programmes were evaluated through incremental cost-effectiveness ratios and net monetary benefits. Decision and parameter uncertainty were subjected to value-of-information analyses.

Results

The current UC and one of three MF programmes dominated the other alternatives. The MF programme was more costly but also more effective than UC at an incremental cost-effectiveness ratio of €8,209.20/additional asthma case prevented. The value of perfect information to reduce uncertainty was €291.6M at its lowest. Most of the uncertainty in the cost-effectiveness threshold was attributable to the probability and cost estimates for low-risk children.

Conclusion

This study supports the feasibility of a structured programme that simultaneously addresses exposure to house dust mites, pet dander, environmental tobacco, and breast-feeding as a cost-effective alternative to UC in the primary prevention of asthma amongst children.
Literature
1.
Johansson, S.G.O., Haahtela, T.: Introduction. In: Johansson, S.G.O., Haahtela, T. (eds.) Prevention of allergy and allergic asthma: WHO project report and guidelines, pp. xiii–xix. Karger, Basel (2004)
2.
Hoogendoom, E.J.I., Feenstra, T.L., Rutten-van Mölken, M.P.M.H.: Inventarisatie van het gebruik en de kosten van zorg voor astma en COPD in Nederland (Inventory of use and cost of care for asthma and COPD in the Netherlands). Rijsksinstituut voor Volksgezondheid en Milieu (National Institute for Public Health and the Environment), Bilthoven (2004)
3.
4.
Eder, W., Ege, M.J., von Mutius, E.: The asthma epidemic. N. Engl. J. Med. 355, 2226–22235 (2006)PubMedCrossRef
5.
6.
Bindels, P.J.E., van der Wouden, J.C., Ponsioen, B.P., Brand, P.L.P., Salomé, P.L., van Hensbergen, W., et al.: Nederlands Huisartsen Genootschap (NHG)-standaard astma bij kinderen: tweede herziening (Dutch College of General Practitioners’ (DCGP’s) guideline on childhood asthma: second version). Huisarts Wet. 49, 557–572 (2006)
7.
Maas, T., Kaper, J., Sheikh, A., Knottnerus, J.A., Wesseling, G., Dompeling, E., et al.: Mono and multifaceted allergen reduction interventions for preventing asthma in children at high risk of developing asthma. Cochrane Database Syst. Rev. 3, CD006480 (2009)PubMed
8.
Weiss, K., Haus, M., Iikura, Y.: The costs of allergy and asthma and the potential benefit of prevention strategies. In: Johansson, S.G.O., Haahtela, T. (eds.) Prevention of allergy and allergic asthma: world allergy organization project report and guidelines, pp. 184–192. Karger, Basel (2004)CrossRef
9.
Drummond, M.F., Sculpher, M.J., Torrance, G.W., O’Brien, B.J., Stoddart, G.L.: Methods for the economic evaluation of health care programmes, 3rd edn. Oxford University Press, Oxford (2005)
10.
Briggs, A., Sculpher, M., Claxton, K.: Decision modelling for health economic evaluation. Oxford University Press, Oxford (2006)
11.
Ramos, G.F.P., Kuiper, S., Dompeling, E., van Asselt, A.D., de Grauw, W.J., Knottnerus, J.A., et al.: Structuring and validating a cost-effectiveness model of primary asthma prevention among children. BMC Med. Res. Methodol. 11, 150 (2011)PubMedCrossRefPubMedCentral
12.
Barton, P., Bryan, S., Robinson, S.: Modelling in the economic evaluation of health care: selecting the appropriate approach. J. Health Serv. Res. Policy 9, 110–118 (2004)PubMedCrossRef
13.
Karnon, J., Brown, J.: Selecting a decision model for economic evaluation: a case study and review. Health Care Manag. Sci. 1, 133–140 (1998)PubMedCrossRef
14.
Brennan, A., Chick, S.E., Davis, R.: A taxonomy of model structures for economic evaluation of health technologies. Health Econ. 15, 1295–1310 (2006)PubMedCrossRef
15.
Stahl, J.E.: Modelling methods for pharmacoeconomics and health technology assessment: an overview and guide. Pharmacoeconomics 26, 131–148 (2008)PubMedCrossRef
16.
Detsky, A.S., Naglie, G., Kahn, M.D., Naimark, D., Redelmeier, D.A.: Primer on medical decision analysis: part 2—building a tree. Med. Decis. Making 17, 126–135 (1997)PubMedCrossRef
17.
Kuiper, S., Maas, T., van Schayck, C.P., Muris, J.W.M., Schönberger, H.J.A.M., Dompeling, E., et al.: The Primary Prevention of Asthma in Children (PREVASC) Study: design of a multifaceted prevention program. Pediatr. Allergy Immunol. 16, 321–331 (2005)PubMedCrossRef
18.
Kuiper, S., Muris, J.W., Dompeling, E., Kester, A.D., Wesseling, G., Knottnerus, J.A., et al.: Interactive effect of family history and environmental factors on respiratory tract-related morbidity in infancy. J. Allergy Clin. Immunol. 120, 388–395 (2007)PubMedCrossRef
19.
Schönberger, H.J.A.M., Dompeling, E., Knottnerus, J.A., Maas, T., Muris, J.W., van Weel, C., et al.: The PREVASC study: the clinical effect of a multifaceted educational intervention to prevent childhood asthma. Eur. Respir. J. 25, 660–670 (2005)PubMedCrossRef
20.
Maas, T., Dompeling, E., Muris, J.W., Wesseling, G., Knottnerus, J.A., van Schayck, O.C.: Prevention of asthma in genetically susceptible children: a multifaceted intervention trial focused on feasibility in general practice. Pediatr. Allergy Immunol. 22, 794–802 (2011)PubMedCrossRef
21.
Arshad, S.H., Matthews, S., Gant, C., Hide, D.W.: Effect of allergen avoidance on development of allergic disorders in infancy. Lancet 339, 1493–1497 (1992)PubMedCrossRef
22.
Arshad, S.H., Bateman, B., Matthews, S.M.: Primary prevention of asthma and atopy during childhood by allergen avoidance in infancy: a randomised controlled study. Thorax 58, 489–493 (2003)PubMedCrossRefPubMedCentral
23.
Chan-Yeung, M., Manfreda, J., Dimich-Ward, H., Ferguson, A., Watson, W., Becker, A.: A randomized controlled study on the effectiveness of a multifaceted intervention program in the primary prevention of asthma in high-risk infants. Arch. Pediatr. Adolsec. Med. 154, 657–663 (2000)CrossRef
24.
Chan-Yeung, M., Ferguson, A., Watson, W., Dimich-Ward, H., Rousseau, R., Lilley, M., et al.: The Canadian Childhood Asthma Primary Prevention Study: outcomes at 7 years of age. J. Allergy Clin. Immunol. 116, 49–55 (2005)PubMedCrossRef
25.
Mihrshahi, S., Peat, J.K., Webb, K., Tovey, E.R., Marks, G.B., Mellis, C.M., et al.: The Childhood Asthma Prevention Study (CAPS): design and research protocol of a randomized trial for the primary prevention of asthma. Control. Clin. Trials 22, 333–354 (2001)PubMedCrossRef
26.
Marks, G.B., Mihrshahi, S., Kemp, A.S., Tovey, E.R., Webb, K., Almqvist, C., et al.: Prevention of asthma during the first 5 years of life: a randomized controlled trial. J. Allergy Clin. Immunol. 118, 53–61 (2006)PubMedCrossRef
27.
Zeiger, R.S., Heller, S., Mellon, M.H., Forsythe, A.B., O’Conner, R.D., Hamburger, R.N., et al.: Effect of combined maternal and infant food-allergen avoidance on development of atopy in early infancy: a randomized study. J. Allergy Clin. Immunol. 84, 72–89 (1989)PubMedCrossRef
28.
Zeiger, R.S., Heller, S.: The development and prediction of atopy in high-risk children: follow-up at age seven years in a prospective randomized study of combined maternal and infant food allergen avoidance. J. Allergy Clin. Immunol. 95, 1178–1190 (1995)CrossRef
29.
Schönberger, H.J.A.M., van Schayck, C.P.M.: Prevention of asthma in genetically predisposed children in primary care—from clinical efficacy to a feasible intervention programme. Clin. Exp. Allergy 28, 1325–1331 (1998)PubMedCrossRef
30.
Yang, Q., Atkinson, M., Erickson, J.D.: Method of weighted proportion of reproductive-aged women taking folic acid supplements to predict a neural tube defect rate decline. Birth Defects Res. A Clin. Mol. Teratol. 67, 959–967 (2003)PubMedCrossRef
31.
Hakkart-van Roijen, L., Tan, S.S., Bouwmans, C.A.M.: Handleiding voor Kostenonderzoek: Methoden en Standaard Kostprijzen voor Economische Evaluaties in de Gezondheidszorg (Manual for costing in economic evaluations: methods and standard cost prices for economic evaluations in health care). College voor Zorgverzekeringen (Health Care Insurance Board), Diemen (2010)
32.
33.
34.
Nuijten, M.J.C.: Incorporation of statistical uncertainty in health economic modelling studies using second-order Monte Carlo simulations. Pharmacoeconomics. 22, 759–769 (2004)PubMedCrossRef
35.
Barton, G.R., Briggs, A.H., Fenwick, E.A.L.: Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfect information (EVPI). Value Health 11, 886–897 (2008)PubMedCrossRef
36.
Claxton, K., Posnett, J.: An economic approach to clinical trial design and research priority-setting. Health Econ. 5, 513–524 (1996)PubMedCrossRef
37.
Claxton, K.: Exploring uncertainty in cost-effectiveness analysis. Pharmacoeconomics. 26, 781–798 (2008)PubMedCrossRef
38.
Zinnige en duurzame zorg (Sensible and sustainable care). Raad voor de Volksgezondheid en Zorg (Council for Public Health and Health Care), Zoetermeer (2006)
39.
de Mesa, E.G., Hidalgo, I., Christidis, P., Ciscar, J.C., Vegas, E., Ibaretta, D.: Modeling the impact of genetic screening technologies on healthcare: theoretical model for asthma in children. Mol. Diag. Ther. 11, 313–323 (2007)CrossRef
40.
Andronis, L., Barton, P., Bryan, S.: Sensitivity analysis in economic evaluation: an audit of NICE current practice and a review of its use and value in decision-making. Health Technol. Assess. 13, 1–61 (2009)CrossRef
41.
To, T., Dell, S., Dick, P., Cicutto, L.: The burden of illness experienced by young children associated with asthma: a population-based cohort study. J. Asthma 45, 45–49 (2008)PubMedCrossRef
42.
43.
Corso, P., Fertig, A.: The long-term economic costs of asthma. Partnership for America’s Economic Success Issue Paper. 13 (2009)
Metadata
Title
Cost-effectiveness of primary prevention of paediatric asthma: a decision-analytic model
Authors
G. Feljandro P. Ramos
Antoinette D. I. van Asselt
Sandra Kuiper
Johan L. Severens
Tanja Maas
Edward Dompeling
J. André Knottnerus
Onno C. P. van Schayck
Publication date
01-11-2014
Publisher
Springer Berlin Heidelberg
Published in
The European Journal of Health Economics / Issue 8/2014
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-013-0532-x

Other articles of this Issue 8/2014

The European Journal of Health Economics 8/2014 Go to the issue

Erratum

Erratum to: Cost-effectiveness of febuxostat in chronic gout

Editorial

Considering productivity loss in cost-effectiveness analysis: a new approach

Original Paper

On social polarization and ordinal variables: the case of self-assessed health

Original Paper

The impact of memantine in combination with acetylcholinesterase inhibitors on admission of patients with Alzheimer’s disease to nursing homes: cost-effectiveness analysis in France

Original Paper

The influence of waiting times on cost-effectiveness: a case study of colorectal cancer mass screening

Original Paper

Population ageing and healthcare expenditure projections: new evidence from a time to death approach